Azacytosine analogs and derivatives

Details Azacytosine analogs and derivatives Azacytosine analogs and derivatives

2007-07-31

2007-07-31

Balasubramanian, Venkataraman (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C544S205000, C544S206000, C544S218000, C544S220000

Reexamination Certificate

active

11077862

ABSTRACT:
Compounds and compositions of azacytosine analogs and derivatives are provided. In one aspect of the invention, analogs or derivatives of decitabine and azacitidine are provided with modification at the 4- and 6-position of the triazine ring, at the 1′–6′ position of the ribose ring, or combinations thereof. Methods of synthesizing and manufacturing these analogs and derivatives are also provided. These compounds can be formulated into pharmaceutical compositions that can be used for treating any disease that is sensitive to the treatment with decitabine or azacitidine, such as hematological disorders and cancer.

REFERENCES:
patent: 4690918 (1987-09-01), Beppu et al.
patent: 5736531 (1998-04-01), Von Borstel et al.
patent: 5856090 (1999-01-01), Epstein
patent: 5968914 (1999-10-01), Von Borstel et al.
patent: 6136791 (2000-10-01), Nyce
patent: 6432924 (2002-08-01), Nyce
patent: 2001/0012835 (2001-08-01), Fine et al.
patent: 2002/0114809 (2002-08-01), Rubinfeld et al.
patent: 2003/0039689 (2003-02-01), Chen et al.
patent: 2003/0045497 (2003-03-01), Widegren et al.
patent: 2003/0108588 (2003-06-01), Chen et al.
patent: 2003/0147813 (2003-08-01), Lyons
patent: 2003/0158598 (2003-08-01), Ashton et al.
patent: 2004/0019036 (2004-01-01), Robin et al.
patent: 269077 (1990-04-01), None
patent: 1922702 (1969-11-01), None
patent: 2105468 (1971-11-01), None
patent: 0286958 (1988-10-01), None
patent: 0334368 (1989-09-01), None
patent: 0393575 (1990-10-01), None
patent: 0515156 (1992-11-01), None
patent: 05219974 (1993-08-01), None
patent: 2002223753 (2002-08-01), None
patent: 2002370939 (2002-12-01), None
patent: 2003310293 (2003-11-01), None
patent: WO 93/01202 (1993-01-01), None
patent: WO 93/07295 (1993-04-01), None
patent: WO 94/26761 (1994-11-01), None
patent: WO 94/27632 (1994-12-01), None
patent: WO 95/15373 (1995-06-01), None
patent: WO 96/11280 (1996-04-01), None
patent: WO 96/36693 (1996-11-01), None
patent: WO 96/39035 (1996-12-01), None
patent: WO 96/40165 (1996-12-01), None
patent: WO 97/23230 (1997-07-01), None
patent: WO 98/16186 (1998-04-01), None
patent: WO 00/23112 (2000-04-01), None
patent: WO 00/40269 (2000-07-01), None
patent: WO 00/62075 (2000-10-01), None
patent: WO 00/74634 (2000-12-01), None
patent: WO 01/29235 (2001-04-01), None
patent: WO 01/69262 (2001-09-01), None
patent: WO 02/21140 (2002-03-01), None
patent: WO 02/053138 (2002-07-01), None
patent: WO 02/057425 (2002-07-01), None
patent: WO 02/069903 (2002-09-01), None
patent: WO 02/076486 (2002-10-01), None
patent: WO 02/083705 (2002-10-01), None
patent: WO 02/085400 (2002-10-01), None
patent: WO 02/087586 (2002-11-01), None
patent: WO 02/101353 (2002-12-01), None
patent: WO 03/012085 (2003-02-01), None
patent: WO 03/012112 (2003-02-01), None
patent: WO 03/020252 (2003-03-01), None
patent: WO 03/026574 (2003-04-01), None
patent: WO 03/031932 (2003-04-01), None
patent: WO 03/040363 (2003-05-01), None
patent: WO 03/043631 (2003-05-01), None
patent: WO 03/046190 (2003-06-01), None
patent: WO 03/062826 (2003-07-01), None
patent: WO 03/065995 (2003-08-01), None
patent: WO 03/076660 (2003-09-01), None
patent: WO 03/092623 (2003-11-01), None
patent: WO 03/104427 (2003-12-01), None
patent: PCT/US04/22367 (2004-07-01), None
Issa. J.P., Current Opinion in Oncology 15(6): 446-451, 2003.
Von Hoff, et al., “5-Azacytidine. A New Anticancer Drug With Effectiveness in Acute Myelogenous Leukemia,”Annals of Internal Medicine(1976) 85(2), pp. 237-245.
Brown, R. et al. Demethylation of DNA by decitabine in cancer chemotherapy.Expert Rev Anticancer Ther. 2004; 4(4): 501-510.
Gilbert, J. et al. The Clinical Application of Targeting Cancer through Histone Acetylation and Hypomethylation.Clinical Cancer Research. 2004; 10: 4589-4596.
Herman, J. G. et al. Gene Silencing in Cancer in Association with Promoter Hypermethylation.The New England Journal of Medicine. 2003; 349(21): 2042-2054.
Leone, G. et al. DNA methylation and demethylating drugs in myelodysplastic syndromes and secondary leukemias.Haematologica. 2002; 87(12): 1324-1341.
Leone, G. et al. Inhibitors of DNA methylation in the treatment of hematological malignancies and MDS.Clin Immunol. 2003; 109(1): 89-102.
Baylin, S.B. et al. Alterations in DNA Methylation: A Fundamental Aspect of Neoplasia.Cancer Res. 1998; 72:141-196.
Daskalakis, M. et al. Expression of a Hypermethylated and Silenced P15/INK4B Gene in a Subgroup of MDS Patients is Restored by Treatment With The Methylation Inhibitor 5-AZA-2′-Deoxycytidine.Abstracts Leukemia Research. 2001; Suppl. No. 1:S16-S17.
Esteller, M. A Gene Hypermethylation Profile of Human Cancer.Cancer Research. 2001; 61:3225-3229.
Esteller, M. CpG Island Hypermethylation and Tumor Suppressor Genes: a Booming Present, a Brighter Future.Oncogene. 2002; 21:5427-5440.
Esteller, M. Epigenetic Lesions Causing Genetic Lesions in Human Cancer: Promoter Hypermethylation of DNA Repair Genes.European Journal of Cancer. 2000; 36:2294-2300.
Gagnon, J. et al. Interaction of 5-aza-2′-deoxyctidine and Depsipeptide on Antineoplastic Activity and Activation of 14-3-3σ, E-Cadherin And Tissue Inhibitor of Metalloproteinase 3 Expression in Human Breast Carcinoma Cells.Anti-Cancer Drugs. 2003; 14(3):193-202.
Jones, P.A. DNA Methylation And Cancer.Oncogene, 2002; 21:5358-5360.
Jones, P.A. et al. The Fundamental Role of Epigenetic Events in Cancer.Nature Reviews/Genetics. 2002; 3:415-428.
Jones, P.A. et al. The Role of DNA Methylation in Cancer.Adv. Cancer Res. 1990; 54:1-23.
Karpf, A.R. et al. Reactivating The Expression of Methylation Silenced Genes in Human Cancer.Oncogene. 2002; 21:5496-5503.
La Rosse, P. et al.In VitroEfficacy of Combined Treatment Depends on the Underlying Mechanism of Resistance in Imatinib-Resistant Bcr-Abl positive Cell Lines.Blood First Edition Paper. prepublished online 2003; DOI 10.1182/blood-2003-04-1074, pp. 1-39.
Nephew, K.P. et al. Epigenetic Gene Silencing in Cancer Initiation And Progression.Cancer Letters. 2003; 190: 125-133.
Paz, M.F. et al. A Systematic Profile of DNA Methylation in Human Cancer Cell Lines.Cancer Research. 2003; 63:1114-1121.
Primeau, M. et al. Synergistic Antineoplastic Action of DNA Methylation Inhibitor 5-AZA-2′-Deoxycytidine and Histone Deacetylase Inhibitor Depsipeptide on Human Breast Carcinoma Cells.Int. J. Cancer. 2003; 103:177-184.
Santini, V. et al. Changes in DNA Methylation in Neoplasia: Pathophysiology and Therapeutic Implications.Annals of Internal Medicine. 2001; 134:573-586.
Schrump, D.S. et al. Phase 1 Study of Sequential Deoxyazacytidine/Depsipeptide Infusion in Patients With Malignancies Involving Lungs or Pleura.Clinical Lung Cancer. 2002; 186-192.
Shaker, S. et al. Preclinical Evaluation of Antineoplastic Activity of Inhibitors of DNA Methylation (5-aza-2′-deoxycytidine) and Histone Deacetylation (Trichostatin A, Depsipeptide) in Combination Against Myeloid Leukemic Cells.Leukemia Research. 2003; 27:437-444.
Smiraglia, D.J. et al. The Study of Aberrant Methylation in CancerviaRestriction Landmark Genomic Scanning.Oncogene. 2002; 21:5414-5426.
Wajed, S.A. et al. DNA Methylation: An Alternative Pathway to Cancer.Annals of Surgery2001; 234(1):10-20.
Weiser, T.S. Sequential 5-Aza-2′-Deoxycytidine-Depsipeptide FR901228 Treatment Induces Apoptosis Preferentially in Cancer Cells And Facilities Their Recognition by Cytolytic T Lymphocytes Specific for NY-ESO-1.Journal of Immunotherapy. 2001; 24(2):151-161.

Affiliated with

Also associated with

Rating

Azacytosine analogs and derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Azacytosine analogs and derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Azacytosine analogs and derivatives will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3729760